Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Treasury Shares (2022 - 2025)

Caribou Biosciences (CRBU) has disclosed Treasury Shares for 4 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Treasury Shares rose 71.14% to $2.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $2.2 million, a 71.14% increase, with the full-year FY2024 number at $1.3 million, up 531.74% from a year prior.
  • Treasury Shares was $2.2 million for Q3 2025 at Caribou Biosciences, up from $1.7 million in the prior quarter.
  • In the past five years, Treasury Shares ranged from a high of $2.2 million in Q3 2025 to a low of $60000.0 in Q1 2022.
  • A 4-year average of $846915.5 and a median of $259769.0 in 2022 define the central range for Treasury Shares.
  • Peak YoY movement for Treasury Shares: plummeted 35.16% in 2023, then surged 673.49% in 2024.
  • Caribou Biosciences' Treasury Shares stood at $256146.0 in 2022, then fell by 19.83% to $205357.0 in 2023, then skyrocketed by 531.74% to $1.3 million in 2024, then skyrocketed by 71.86% to $2.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Treasury Shares are $2.2 million (Q3 2025), $1.7 million (Q2 2025), and $2.2 million (Q1 2025).